Skip to main content
SpringerLink
Log in
Book cover

Urologic Oncology pp 1–16Cite as

Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer

  • Living reference work entry
  • First Online:

  • 153 Accesses

Abstract

The current treatment paradigm of prostate cancer has increasingly emphasized the importance of reliable biomarkers that help stratify patients and aid in decision-making. The rapid development of numerous novel biomarkers in the past decade has made this process much more challenging. In this chapter, we provide a comprehensive review of the widely used biomarkers that are supported by clinical evidence. Specifically, the focus will be on diagnostic (PHI®, 4K score, IsoPSA®, SelectMDx®, ConfirmMDx®, PCA3, TMPRSS2:ERG gene fusion) and prognostic (OncotypeDX GPS®, Prolaris®, ProMark®, Decipher®) biomarkers. In order to better understand the value of these biomarkers in clinical decision-making, there will be an emphasis on clinical context as the literature is reviewed.

This is a preview of subscription content, log in via an institution.

References

  • Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27(3):253–63.

    Article  CAS  PubMed  Google Scholar 

  • Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, et al. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int. 2015;115(3):419–29.

    Article  PubMed  Google Scholar 

  • Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014;192(2):409–14.

    Article  PubMed  Google Scholar 

  • Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(11):2591–600.

    Article  CAS  Google Scholar 

  • Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London, England). 2012;380(9858):2018–27.

    Article  Google Scholar 

  • Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(11):1428–34.

    Article  CAS  Google Scholar 

  • Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30(6):1025–31.

    Article  PubMed  Google Scholar 

  • Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68(1):123–31.

    Article  PubMed  Google Scholar 

  • Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113(3):382–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185(6):2119–25.

    Article  PubMed  Google Scholar 

  • Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596–9.

    Article  CAS  PubMed  Google Scholar 

  • Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89(5):1038–46.

    Article  PubMed  PubMed Central  Google Scholar 

  • Filella X, Foj L, Auge JM, Molina R, Alcover J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin Chem Lab Med. 2014;52(9):1347–55.

    Article  CAS  PubMed  Google Scholar 

  • Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64(2):311–5; discussion 5–6

    Article  PubMed  Google Scholar 

  • Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(5):848–53.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gnanapragasam VJ, Burling K, George A, Stearn S, Warren A, Barrett T, et al. The prostate health index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. Sci Rep. 2016;6:35364.

    Google Scholar 

  • Gore JL, Plessis MD, Santiago-Jimenez M, Yousefi K, Thompson DJS, Karsh L, et al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: interim results from the multicenter prospective PRO-IMPACT study. Cancer. 2017;123(15):2850–2859. https://doi.org/10.1002/cncr.30665. Epub 2017 Apr 19.

  • Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54(5):1081–8.

    Article  PubMed  Google Scholar 

  • Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, et al. Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features. Eur Urol. 2018;73(2):168–175. https://doi.org/10.1016/j.eururo.2017.03.036. Epub 2017 Apr 8

  • Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–60.

    Article  PubMed  Google Scholar 

  • Klein EA, Haddad Z, Yousefi K, Lam LL, Wang Q, Choeurng V, et al. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology. 2016;90:148–52.

    Article  PubMed  Google Scholar 

  • Klein EA, Chait A, Hafron JM, Kernen KM, Manickam K, Stephenson AJ, et al. The single-parameter, structure-based IsoPSA assay demonstrates improved diagnostic accuracy for detection of any prostate cancer and high-grade prostate Cancer compared to a concentration-based assay of total prostate-specific antigen: a preliminary report. Eur Urol. 2017;72(6):942–949.

    Google Scholar 

  • Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010;183(4):1355–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Leyten GHJM, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–42.

    Article  CAS  PubMed  Google Scholar 

  • Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(13):3061–70.

    Article  CAS  Google Scholar 

  • Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1.2016. J Natl Compr Cancer Netw: JNCCN. 2016;14(1):19–30.

    Article  Google Scholar 

  • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.

  • Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008;3(5):e2318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68(1):139–46.

    Article  CAS  PubMed  Google Scholar 

  • Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192(4):1081–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomark Prev. 2012;21(9):1497–509.

    Article  Google Scholar 

  • Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011;59(3):422–9.

    Article  PubMed  Google Scholar 

  • Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. Prostate Cancer Prostatic Dis. 2014;17(1):64–9. https://doi.org/10.1038/pcan.2013.49. Epub 2013 Oct 22.

  • Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, et al. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci. 2014a;12:40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer. 2014b;111(6):1201–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014;30(4):547–53.

    Article  PubMed  Google Scholar 

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  • Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol. 2015;68(2):207–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem. 2013;59(1):306–14.

    Article  CAS  PubMed  Google Scholar 

  • Stewart GD, Van Neste L, Delvenne P, Delree P, Delga A, McNeill SA, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013;189(3):1110–6.

    Article  PubMed  Google Scholar 

  • Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.

    Article  CAS  PubMed  Google Scholar 

  • Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.

    Article  PubMed  Google Scholar 

  • Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–62.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, et al. Prostate health index density improves detection of clinically-significant prostate cancer. BJU Int. 2017;120:793–8.

    Article  CAS  PubMed  Google Scholar 

  • Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 2012;110(1):56–62.

    Article  CAS  PubMed  Google Scholar 

  • Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72(11):1248–61.

    Article  CAS  PubMed  Google Scholar 

  • Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70(5):740–8.

    Article  CAS  PubMed  Google Scholar 

  • Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(15):2493–8.

    Article  Google Scholar 

  • Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32(36):4066–72.

    Article  CAS  Google Scholar 

  • Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–50.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    Derya Tilki

  2. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    Derya Tilki & Felix K. Chun

  3. Department of Urology Sidney Kimmel Cancer Center, Thomas Jefferson University/Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Thenappan Chandrasekar

  4. The Vancouver Prostate Centre and Department of Urological Sciences, University of British Columbia, Vancouver, Canada

    Alexander Kretschmer

  5. Department of Urology, Ludwig-Maximilians University Munich, Munich, Germany

    Alexander Kretschmer

Authors
  1. Derya Tilki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thenappan Chandrasekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Kretschmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felix K. Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Derya Tilki .

Editor information

Editors and Affiliations

  1. Urologie, Univ Lübeck, Lübeck, Schleswig-Holstein, Germany

    Axel Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Martini-Klinik am UKE GmbH, Hamburg, Germany

    Thomas Steuber

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Tilki, D., Chandrasekar, T., Kretschmer, A., Chun, F.K. (2018). Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_68-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_68-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation